MACSF

COMMUNIQUÉS West-GlobeNewswire

Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
07/08/2024
TARRYTOWN, N.Y., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) announces the following September 2024 investor events: Investor Conference Presentations • Morgan Stanley 22 nd Annual [...]
Elutia Announces Second Quarter 2024 Results
07/08/2024
Launch Production of EluPro® Underway, Commercial Team Expansion Continues, Financial Position Solidified SILVER SPRING, Md., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a [...]
Generation Bio Reports Second Quarter 2024 Financial Results
07/08/2024
Cash balance of $217 million still expected to fund operations into 2H 2027 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company innovating genetic medicines [...]
Relmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
07/08/2024
Outcome of pre-planned Reliance II interim analysis anticipated by YE 2024 Enrollment in Phase 3 Reliance II study expected to be completed by YE 2024 Preparations on track to initiate Phase 1 study for REL-P11 for [...]
Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07/08/2024
-Recently Held Positive Pre-BLA Meeting with FDA with Aim to Accelerate Approval Pathway of Deramiocel for the Treatment of Duchenne Muscular Dystrophy- -Phase 3, HOPE-3 Trial of Deramiocel in DMD Fully Enrolled; On [...]
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
07/08/2024
REDWOOD CITY, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update
07/08/2024
Cemacabtagene Ansegedleucel (Cema-Cel): 1L Consolidation in Large B-Cell Lymphoma (LBCL) Pivotal Phase 2 ALPHA3 Trial Initiated in June 2024 Patient Screening for Minimal Residual Disease (MRD) and Enrollment Proceeding [...]
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
07/08/2024
SAN CARLOS, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, [...]
Keros Therapeutics Reports Second Quarter 2024 Financial Results
07/08/2024
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
electroCore Announces Second Quarter 2024 Financial Results
07/08/2024
Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023 Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY, N.J., Aug. 07, [...]
LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
07/08/2024
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye to [...]
Assertio Reports Second Quarter 2024 Financial Results
07/08/2024
Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments Increases to $88.4 [...]
Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
07/08/2024
Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 [...]
Angiex Announces First Patient Dosed in Phase 1 Clinical Trial of AGX101, a novel TM4SF1-Directed Antibody-Drug Conjugate for the Treatment of Solid Tumors
07/08/2024
CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- August 7, 2024: Angiex, a developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, announced that the first patient has been dosed [...]
Milestone Scientific Announces Strategic Partnership with Axial Biologics to Distribute CompuFlo® in New Jersey, Texas, and Florida
07/08/2024
ROSELAND, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS) , a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced a [...]
XYMOGEN XPERIENCE Dedicated Exclusively to Elevating Women’s Health
07/08/2024
A renowned lineup of experts will address wellness insights core to women’s health beyond hormones ORLANDO, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- XYMOGEN ® is excited to announce its XYMOGEN XPERIENCE Fall 2024 (XX [...]
Asensus Surgical 2024 Special Meeting of Stockholders Is Adjourned
07/08/2024
RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc. (NYSE American: ASXC), a global leader of innovative digital solutions for the operating room, today announced that the Company’s [...]
Zevra Therapeutics to Present at Canaccord Genuity’s 44th Annual Growth Conference
07/08/2024
CELEBRATION, Fla., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief [...]
Groundbreaking Voice of the Patient Report for pediatric low-grade glioma (pLGG) published by Pediatric Brain Tumor Foundation
07/08/2024
Report documents the experiences of pLGG patients, survivors, their families, and caregivers to inform future drug development for pLGG, the most common brain tumor type in children NEW YORK, Aug. 07, 2024 (GLOBE [...]

Pages